Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nonresponse to 18-month lamivudine monotherapy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation.

Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Jul 2006

Sheu Ming-Jen, Lin Ching-Yih, Sun Chi-Shu, Kuo Hsing-Tao, Koay Lok-Beng, Lee Chuan, Chen Jyh-Jou, Tang Ling-Yu, Tsai Sun-Lung

Abstract excerpt

Molecular epidemiologic studies have indicated the possible existence of mixed infection of different hepatitis B virus (HBV) genotypes in chronic hepatitis B (CH-B) carriers, but the effect of dual HBV genotype B and C infection on the efficacy of lamivudine therapy remains unclear. We report four CH-B patients with dual HBV genotype B and C infection and acute exacerbation who received lamivudine monotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Genotype

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Source

Identifiers

PMID: 16877240
DOI: 10.1016/S0929-6646(09)60155-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nonresponse to 18-month lamivudine monotherapy in chronic hepatitis B patients with dual genotype B and C infection and acute exacerbation.PMID 16877240Read ↗

Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited.Semantic proximity Read ↗

Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.Semantic proximity Read ↗

Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.Semantic proximity Read ↗

Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection.Semantic proximity Read ↗

Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.Semantic proximity Read ↗

Mixed infections of hepatitis C virus as a factor in acute exacerbations of chronic type C hepatitis.Semantic proximity Read ↗

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.Semantic proximity Read ↗

Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy.Semantic proximity Read ↗

Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.Semantic proximity Read ↗

Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.